Status:
COMPLETED
Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial
Lead Sponsor:
KU Leuven
Conditions:
Irritable Bowel Syndrome (IBS)
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
Purpose: To evaluate the efficiency of Irritable Bowel Syndrome (IBS) patients treatment with the H1-receptor antagonist ebastine. Design: Double blind randomized placebo controlled trial. IBS pati...
Eligibility Criteria
Inclusion
- Irritable Bowel Syndrome (IBS) (ROME III criteria): subtype with diarrhea or mixed form
- age 18-65 years
Exclusion
- IBS subtype with constipation
- medication: antidepressants or H1-receptor antagonists
- pregnancy, breast feeding
- co-morbidity: severe kidney- and/or liver disease or other gastrointestinal diseases
Key Trial Info
Start Date :
November 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 2 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01908465
Start Date
November 1 2013
End Date
November 2 2022
Last Update
February 8 2023
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
UZ Antwerpen
Edegem, Antwerpen, Belgium, 2650
2
ZOL (Ziekenhuis Oost-Limburg)
Genk, Limburg, Belgium, 3600
3
UZ Gent
Ghent, Oost-Vlaanderen, Belgium, 9000
4
AZ Sint-Elizabeth Zottegem
Zottegem, Oost-Vlaanderen, Belgium, 9620